Personalized medicine is at an early stage of development. Scientists found that some cancer cells have particular proteins in the cell and others don’t. Sometimes, cancer cells have far more of a particular protein than healthy cells. Genetic testing of cancer cells and normal cells helps doctors customize treatment to individual patient needs. Personalized treatments may cause fewer side effects than standard options. Some people are already benefiting from this approach.
This report contains market size and forecasts of Personalized Cancer Medicine in Global, including the following market information:
Global Personalized Cancer Medicine Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Personalized Cancer Medicine market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Monoclonal Antibodies Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Personalized Cancer Medicine include Abbott, Merck, Novartis, Amgen, Celgene, Bayer, Roche, Astellas and Astrazeneca, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Personalized Cancer Medicine companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Personalized Cancer Medicine Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Personalized Cancer Medicine Market Segment Percentages, by Type, 2021 (%)
Monoclonal Antibodies
Personalized Cancer Vaccines
Other
Global Personalized Cancer Medicine Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Personalized Cancer Medicine Market Segment Percentages, by Application, 2021 (%)
Breast Cancer
Lung Cancer
Chronic Myeloid Leukaemia
Bowel Cancer
Other Cancer
Global Personalized Cancer Medicine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Personalized Cancer Medicine Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Personalized Cancer Medicine revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Personalized Cancer Medicine revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Abbott
Merck
Novartis
Amgen
Celgene
Bayer
Roche
Astellas
Astrazeneca
Johnson & Johnson
Agilent
Takeda